Atara Biotherapeutics, Inc. (0HIY.L)
USD 10.43
(-0.02%)
USD 10.43
(-0.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 264.73 Million USD | 5.99% |
| 2022 | 249.78 Million USD | 32.5% |
| 2021 | 188.51 Million USD | 49.87% |
| 2020 | 125.78 Million USD | 141.14% |
| 2019 | 52.16 Million USD | -1.55% |
| 2018 | 52.98 Million USD | 32.74% |
| 2017 | 39.91 Million USD | 292.17% |
| 2016 | 10.17 Million USD | 3.07% |
| 2015 | 9.87 Million USD | 235.88% |
| 2014 | 2.94 Million USD | -95.32% |
| 2013 | 62.84 Million USD | 683.9% |
| 2012 | 8.01 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 228.15 Million USD | -13.44% |
| 2024 Q1 | 263.57 Million USD | -0.44% |
| 2023 Q1 | 237.12 Million USD | -5.07% |
| 2023 Q3 | 239.62 Million USD | 0.27% |
| 2023 FY | 264.73 Million USD | 5.99% |
| 2023 Q4 | 264.73 Million USD | 10.48% |
| 2023 Q2 | 238.98 Million USD | 0.79% |
| 2022 Q1 | 172.96 Million USD | -8.25% |
| 2022 Q3 | 181.2 Million USD | 1.43% |
| 2022 Q2 | 178.64 Million USD | 3.28% |
| 2022 FY | 249.78 Million USD | 32.5% |
| 2022 Q4 | 249.78 Million USD | 37.85% |
| 2021 Q2 | 125.25 Million USD | -4.09% |
| 2021 FY | 188.51 Million USD | 49.87% |
| 2021 Q1 | 130.6 Million USD | 3.83% |
| 2021 Q4 | 188.51 Million USD | 34.86% |
| 2021 Q3 | 139.78 Million USD | 11.6% |
| 2020 Q2 | 46.98 Million USD | 0.56% |
| 2020 Q4 | 125.78 Million USD | 143.78% |
| 2020 FY | 125.78 Million USD | 141.14% |
| 2020 Q3 | 51.59 Million USD | 9.81% |
| 2020 Q1 | 46.72 Million USD | -10.42% |
| 2019 Q4 | 52.16 Million USD | 12.55% |
| 2019 Q3 | 46.34 Million USD | 10.7% |
| 2019 Q2 | 41.86 Million USD | 2.63% |
| 2019 Q1 | 40.79 Million USD | -23.01% |
| 2019 FY | 52.16 Million USD | -1.55% |
| 2018 FY | 52.98 Million USD | 32.74% |
| 2018 Q4 | 52.98 Million USD | 32.83% |
| 2018 Q3 | 39.88 Million USD | -0.8% |
| 2018 Q2 | 40.2 Million USD | 18.52% |
| 2018 Q1 | 33.92 Million USD | -15.01% |
| 2017 FY | 39.91 Million USD | 292.17% |
| 2017 Q2 | 23.01 Million USD | 167.45% |
| 2017 Q3 | 23.73 Million USD | 3.16% |
| 2017 Q1 | 8.6 Million USD | -15.46% |
| 2017 Q4 | 39.91 Million USD | 68.16% |
| 2016 Q1 | 9.14 Million USD | -7.4% |
| 2016 FY | 10.17 Million USD | 3.07% |
| 2016 Q4 | 10.17 Million USD | -28.4% |
| 2016 Q3 | 14.21 Million USD | 34.5% |
| 2016 Q2 | 10.56 Million USD | 15.58% |
| 2015 Q3 | 6.63 Million USD | -44.03% |
| 2015 Q2 | 11.84 Million USD | 218.21% |
| 2015 Q1 | 3.72 Million USD | 26.63% |
| 2015 FY | 9.87 Million USD | 235.88% |
| 2015 Q4 | 9.87 Million USD | 48.92% |
| 2014 Q1 | 77.57 Million USD | 23.43% |
| 2014 Q3 | 77.14 Million USD | 3283.73% |
| 2014 Q2 | 2.28 Million USD | -97.06% |
| 2014 FY | 2.94 Million USD | -95.32% |
| 2014 Q4 | 2.94 Million USD | -96.19% |
| 2013 Q4 | 62.84 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 62.84 Million USD | 683.9% |
| 2012 FY | 8.01 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -76.424% |
| Dynavax Technologies Corporation | 375.02 Million USD | 29.409% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 45.691% |
| Perrigo Company plc | 6.04 Billion USD | 95.618% |
| Illumina, Inc. | 4.36 Billion USD | 93.936% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.49% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -35.25% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.616% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.713% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -3.219% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.275% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -609.898% |
| Waters Corporation | 3.47 Billion USD | 92.385% |
| Biogen Inc. | 12.04 Billion USD | 97.802% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -221.152% |
| Evolus, Inc. | 209.68 Million USD | -26.252% |
| Adicet Bio, Inc. | 37.12 Million USD | -613.187% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -285.019% |
| bluebird bio, Inc. | 424.62 Million USD | 37.654% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 59.937% |
| FibroGen, Inc. | 585.72 Million USD | 54.802% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 94.617% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -652.577% |
| Homology Medicines, Inc. | 118.53 Million USD | -123.343% |
| Geron Corporation | 146.12 Million USD | -81.168% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.464% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 57.142% |
| Myriad Genetics, Inc. | 312.9 Million USD | 15.393% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1218.993% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -5.553% |
| Zoetis Inc. | 9.29 Billion USD | 97.152% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -438.342% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 92.448% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 85.993% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 94.859% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -446.465% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 89.831% |
| Verastem, Inc. | 71.18 Million USD | -271.897% |
| Nektar Therapeutics | 267.04 Million USD | 0.865% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 33.36% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -558.119% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 88.993% |
| OPKO Health, Inc. | 622.47 Million USD | 57.471% |
| Exelixis, Inc. | 678.44 Million USD | 60.979% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 74.03% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -130.581% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -2012.135% |
| uniQure N.V. | 624.01 Million USD | 57.576% |
| Imunon, Inc. | 8.53 Million USD | -3003.42% |
| Blueprint Medicines Corporation | 918.64 Million USD | 71.182% |
| Insmed Incorporated | 1.66 Billion USD | 84.069% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 83.95% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -109.942% |
| TG Therapeutics, Inc. | 169.08 Million USD | -56.569% |
| Incyte Corporation | 1.59 Billion USD | 83.374% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 77.671% |